Loading asset research
Outlook Therapeutics Inc. Common Stock
OTLKNasdaq · USD · StocksQuote as of · Exchange session not verified$0.6577
-0.50%
Today
OTLK
Loading 1D prices…
Market cap
$160.7M
Volume
3.3M
52w high
$2.5452w low
$0.161Company profile
Outlook Therapeutics Inc. Common Stock
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Iselin, NJ, United States
Employees
17
Fiscal year end
0930
CIK
1649989
Session & valuation
Open$0.67
Previous close$0.661
Day high$0.68
Day low$0.65
30-day avg. volume17M
Outstanding shares243.4M
Diluted EPS-$0.51
Latest annual period
P/E (trailing)-1.29
P/E (forward)-5.50
Price / book-11.79
Beta0.75
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MOLNMolecular Partners AG American Depositary Shares | $160.9M | — | — | -$1.65 | 0.00% | Buy |
| HUMAHumacyte Inc. Common Stock | $157.7M | $2M | -2003.59% | -$0.26 | +0.25% | Buy |
| TNYATenaya Therapeutics Inc. Common Stock | $143.5M | $0.00 | — | -$0.59 | -1.29% | Buy |
| LENZLENZ Therapeutics Inc. Common Stock | $142M | $19.1M | -430.25% | -$2.85 | -4.13% | Buy |
| CRBUCaribou Biosciences Inc. Common Stock | $136.2M | $11.2M | -1327.40% | -$1.59 | -6.57% | Buy |